Annotation Detail
Information
- Associated Genes
- BRCA1
- Associated Variants
-
BRCA1 LOSS-OF-FUNCTION
BRCA1 LOSS-OF-FUNCTION - Associated Disease
- ovarian cancer
- Source Database
- CIViC Evidence
- Description
- 664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative. Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant.
- Variant Origin
- germline
- Variant Origin
- Rare Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1675
- Gene URL
- https://civic.genome.wustl.edu/links/genes/6
- Variant URL
- https://civic.genome.wustl.edu/links/variants/185
- Rating
- 3
- Evidence Type
- Prognostic
- Disease
- Ovarian Cancer
- Evidence Direction
- Supports
- Evidence Level
- B
- Clinical Significance
- Better Outcome
- Pubmed
- 26740259
Drugs